Abstract 17P
Background
In Australia, Indigenous people are natives and custodians of land. The mortality risk is more than double in Indigenous breast cancer women as compared to non- Indigenous women but carries lower incidence risk. Between 2001 and 2010 Indigenous Western Australian women who developed breast cancer were four times more likely to die of the disease than non-Indigenous women of the same age. The data is scarce but many factors are being studied. The effect of remoteness on mortality of indigenous women still needed to be established. The aim is to analyse remoteness as a factor causing effect on survival in Indigenous breast cancer women.
Methods
The data is collected retrospectively from Western Australian cancer Registry mostly, among other sources. A cohort of 100 patients was selected from database including half of indigenous and half non-indigenous women (1:1). At time of writing, 37 Indigenous and 33 Non–Indigenous breast cancer women data was available. The data collected, to analyze the median survival time (months) of patients with respect to Distance (Metropolitan vs Rural) and Indigenous & Non-Indigenous status.
Results
In survival analysis, it has been observed that both indigenous and non-indigenous who live in metropolitan showed better 10 year survival ; 184 months while who were in rural area showed reduced median survival time 130 months and differences among them was found to be significant (p = 0.03), suggesting better survival was associated with patients who live in metropolitan area. However, on analyzing the survival of Indigenous patients with respect to distance, it wasn’t statistically significant (p = 0.19) but still showed higher median survival for patients living in metropolitan area (153 months) as compared to remote rural areas (110 months). Further analyzing indigenous breast cancer patients outcomes with respect to metro area (153 months), 1000km or less and greater then 1000km (87 months); higher survival benefit trend for patient’s living close to metro area.
Conclusions
The data suggest that the Indigenous breast cancer women have inferior survival outcomes with respect to distance from metropolitan area, highlighting a strong co-relation of remoteness and survival disadvantage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Khan, A. Redfern.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract